Development-stage index

Phase 3Peptide Trials.

Explore every Phase 3 peptide study in the local registry snapshot. Compare recruitment, sponsors, therapeutic areas, enrollment, results, publications and study geography.

Studies: 578
Recruiting: 91
Completed: 322
Results posted: 210
Countries: 84
Avg enrollment: 664

Velocity

Phase 3 trials by start year

Study start year · indexed snapshot

Development

Trials by phase

632phase labels

Early Phase 10

Phase 10

Phase 254

Phase 3578

Phase 40

Industry

Leading sponsors

Novo Nordisk37

Sanofi36

Eli Lilly29

Shire21

GlaxoSmithKline17

Ipsen16

Amgen11

Novartis10

Therapeutic areas

Condition groups

Weight loss86

Type 2 diabetes71

Inflammation12

Pain7

Brain health6

Crohn's1

Compound leaders

Most represented peptides.

01Lixisenatide33 02Triptorelin30 03Octreotide25 04Lanreotide23 05Teduglutide22 06Cagrilintide20 07Goserelin18 08Leuprolide18 09Bivalirudin17 10Degarelix16 11Ganirelix16 12Linaclotide16

Study explorer

Search this collection.

578 matching studies

Last registry update first

NCT02115282Phase 3ResultsPubMed

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

GoserelinNational Cancer Institute (NCI)Anatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IV Breast Cancer AJCC v8

Active, not recruiting

Enrollment: 608
Started: Mar 2014
Completion: Jun 2027
Locations: 654
Countries: 2
Updated: Jul 2026

NCT07738276Phase 3PubMed

Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity

Tirzepatide GlucagonShahid Beheshti University of Medical SciencesHeart Failure and Reduced Ejection Fraction · Obesity & Overweight

Not yet recruiting

Enrollment: 60
Started: Jul 2026
Completion: Dec 2027
Locations: 0
Countries: 0
Updated: Jul 2026

NCT05882045Phase 3

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

RetatrutideEli LillyObesity · Cardiovascular Diseases

Completed

Enrollment: 1,946
Started: May 2023
Completion: May 2026
Locations: 169
Countries: 10
Updated: Jul 2026

NCT05929079Phase 3

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

RetatrutideEli LillyType 2 Diabetes · Obesity

Completed

Enrollment: 1,152
Started: Jul 2023
Completion: Jun 2026
Locations: 98
Countries: 8
Updated: Jul 2026

NCT06649344Phase 3

A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

SemaglutideFujian Shengdi Pharmaceutical Co., Ltd.Type 2 Diabetes

Completed

Enrollment: 884
Started: Oct 2024
Completion: Jul 2026
Locations: 1
Countries: 1
Updated: Jul 2026

NCT07228403Phase 3

Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome

GlepaglutideZealand PharmaShort Bowel Syndrome (SBS)

Active, not recruiting

Enrollment: 28
Started: Dec 2025
Completion: Dec 2028
Locations: 16
Countries: 7
Updated: Jul 2026

NCT07564414Phase 3

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

Semaglutide CagrilintideNovo NordiskObesity · Type 2 Diabetes

Recruiting

Enrollment: 2,500
Started: May 2026
Completion: Apr 2028
Locations: 303
Countries: 19
Updated: Jul 2026

NCT00569127Phase 3ResultsPubMed

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

OctreotideNational Cancer Institute (NCI)Colorectal Neuroendocrine Tumor G1 · Gastric Neuroendocrine Tumor G1

Active, not recruiting

Enrollment: 427
Started: Dec 2007
Completion: Jan 2027
Locations: 493
Countries: 1
Updated: Jul 2026

NCT06548100Phase 3

A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

MetreleptinRegeneronGeneralized Lipodystrophy

Completed

Enrollment: 9
Started: Dec 2024
Completion: Jul 2026
Locations: 2
Countries: 1
Updated: Jul 2026

NCT07734792Phase 2 / Phase 3PubMed

Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial

Tirzepatide Glucagonyifang zhuAcute Ischemic Stroke (AIS)

Not yet recruiting

Enrollment: 430
Started: Aug 2026
Completion: Jul 2028
Locations: 1
Countries: 1
Updated: Jul 2026

NCT04484818Phase 3

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Goserelin Triptorelin LeuprolideECOG-ACRIN Cancer Research GroupProstate Carcinoma

Active, not recruiting

Enrollment: 27
Started: Mar 2021
Completion: May 2028
Locations: 115
Countries: 1
Updated: Jul 2026

NCT05050942Phase 3PubMed

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

Octreotide LanreotideCamurus ABGastro-enteropancreatic Neuroendocrine Tumor

Active, not recruiting

Enrollment: 332
Started: Oct 2021
Completion: Nov 2028
Locations: 86
Countries: 12
Updated: Jul 2026

NCT04949633Phase 3PubMed

Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening

OxytocinUniversity Hospital, ToursCervical Ripening · Unfavorable Cervix

Recruiting

Enrollment: 1,494
Started: Sep 2021
Completion: Nov 2027
Locations: 14
Countries: 1
Updated: Jul 2026

NCT06129539Phase 3

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)

TriptorelinDebiopharm International SACentral Precocious Puberty

Active, not recruiting

Enrollment: 56
Started: Jul 2024
Completion: Feb 2028
Locations: 17
Countries: 5
Updated: Jul 2026

NCT06259097Phase 3

Different Medications to Induce Labor

OxytocinIcahn School of Medicine at Mount SinaiPregnancy · Labor

Recruiting

Enrollment: 281
Started: Jul 2024
Completion: Aug 2026
Locations: 2
Countries: 1
Updated: Jul 2026

NCT06930625Phase 3

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

OctreotideDebiopharm International SAAcromegaly

Recruiting

Enrollment: 119
Started: Nov 2025
Completion: Mar 2029
Locations: 72
Countries: 21
Updated: Jul 2026

NCT07011667Phase 3

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

Semaglutide CagrilintideNovo NordiskObesity

Active, not recruiting

Enrollment: 609
Started: Jun 2025
Completion: Oct 2028
Locations: 46
Countries: 1
Updated: Jul 2026

NCT07037433Phase 3

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Maridebart cafraglutideAmgenAtherosclerotic Cardiovascular Disease · Overweight

Recruiting

Enrollment: 12,800
Started: Jul 2025
Completion: Sep 2030
Locations: 782
Countries: 36
Updated: Jul 2026

NCT07340827Phase 3

A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)

CetrorelixMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyInfertility

Recruiting

Enrollment: 266
Started: Feb 2026
Completion: Jul 2028
Locations: 21
Countries: 1
Updated: Jul 2026

NCT07441876Phase 2 / Phase 3

Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

VosoritideBioMarinAchondroplasia

Recruiting

Enrollment: 160
Started: Apr 2026
Completion: Sep 2029
Locations: 19
Countries: 9
Updated: Jul 2026

NCT06077864Phase 3PubMed

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

SurvodutideBoehringer IngelheimObesity

Completed

Enrollment: 5,531
Started: Nov 2023
Completion: Jun 2026
Locations: 540
Countries: 35
Updated: Jul 2026

NCT07035093Phase 3

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

RetatrutideEli LillyObesity · Overweight

Active, not recruiting

Enrollment: 586
Started: May 2025
Completion: Sep 2027
Locations: 40
Countries: 4
Updated: Jul 2026

NCT07218354Phase 3

Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder

SemaglutideVA Office of Research and DevelopmentAlcohol Use Disorder

Not yet recruiting

Enrollment: 622
Started: Jul 2026
Completion: May 2029
Locations: 19
Countries: 1
Updated: Jul 2026

NCT07575399Phase 3

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Maridebart cafraglutide GlucagonAmgenObesity or Overweight

Recruiting

Enrollment: 300
Started: May 2026
Completion: Feb 2028
Locations: 44
Countries: 2
Updated: Jul 2026